FAP and neoplasm: highlighted a novel anti-stroma application, where synNotch drives CAR expression only in stromal cells expressing fibroblast activation protein (FAP), taking advantage of the abundant but tumor-restricted presence of FAP to activate T-cells in a tumor-specific but antigen-independent manner (69).